Browsing Category
Lactose
Preparation of redispersible dry nanoemulsion using chitosan-octenyl succinic anhydride starch…
In this study, chitosan-octenyl succinic anhydride (OSA) starch polyelectrolyte complex (PEC) was investigated as a stabilizer for redispersible dry nanoemulsion. Fenofibrate, a BCS class II lipid-lowering drug, with poor solubility was used as model drug. The dry nanoemulsions were prepared by…
Read More...
Read More...
Impact of unloading kinematics on the occurrence of capping during the production of pharmaceutical…
Capping is a common defect that can occur during the manufacturing of pharmaceutical tablets. Several studies showed that decreasing the unloading speed of the manufacturing cycle plays a role in the occurrence of such defects. Following this idea, we study in this work the influence of the…
Read More...
Read More...
Transformation of Ritonavir Nanocrystal Suspensions into a Redispersible Drug Product via Vacuum…
The present study explored vacuum drum drying (VDD) as potential drying technique for the solidification of crystalline ritonavir nanosuspensions prepared by wet-ball milling. In detail, the impact of drying protectants (mannitol, lactose, trehalose) added to the ritonavir nanosuspension was…
Read More...
Read More...
The role of intrinsic fines in the performance change of expired lactose carriers for DPI…
Dry powder inhalation offers a well-established administration route for either local or systemic drug delivery. Lactose-based powder blends still build the basis of respiratory drug delivery, despite of numerous emerging formulation approaches. The amount of fine lactose excipients, either…
Read More...
Read More...
Proof-of-Concept for Adjusted Surface Energies and Modified Fines as a Novel Concept in Particle…
Currently marketed dry powder inhaler (DPI) medicine lacks drug delivery performance due to insufficient powder dispersion. In carrier-based blends, incomplete drug detachment is typically attributed to excessive adhesion forces between carrier and drug particles. Adding force control agents (FCA)…
Read More...
Read More...
Manufacturing of mini-tablets. Focus and impact of the tooling systems
Mini-tablets are gaining importance for the pharmaceutical industry as several clinical studies and organizations emphasize the benefits for special patient groups such as paediatrics. Mini-tablets can be manufactured on tablet presses using special tooling systems. For industrial purposes often…
Read More...
Read More...
Compression Modulus and Apparent Density of Polymeric Excipients during Compression—Impact on…
The present study focuses on the compaction behavior of polymeric excipients during compression in comparison to nonpolymeric excipients and its consequences on commonly used Heckel analysis. Compression analysis at compaction pressures (CPs) from 50 to 500 MPa was performed using a compaction…
Read More...
Read More...
Influence of rheological behavior of lactose powders on the weight consistency of tablets –…
The 12th APV PBP World Meeting took place from 28 – 31 March 2022 in Rotterdam. There was a poster section at the event where really interesting scientific posters were presented. Therefore we asked the presenting scientists if we could share their work in addition online with the Pharma Excipients…
Read More...
Read More...
Half a Century of Technological Advances in Pulmonary Drug Delivery: A Personal Perspective
The last half century of pulmonary product development is reviewed in the context of the main drivers of innovation, technology development, and the advancement of science. A perspective on development timeframes, patent lifetimes, and the odds of success of developing of new inhaler technologies is…
Read More...
Read More...
Crystallization induced flower-like lactose as potential carriers for dry powder inhaler application
The study documents the flower-like lactose particles as potential carriers to improve Dry Powder Inhaler (DPI) efficiency. The lactose particles (LMx, LMf) are prepared by anti-solvent crystallization and compared with commercial lactose carriers (Inhalac 251; LMc). Formulations of 1.48% w/w drug…
Read More...
Read More...